From Logistics to Lifecycle: Building Advanced Therapy Supply Chains that Scale

As cell and gene therapies approach broader commercialization, the supply chain landscape is undergoing significant transformation. The logistics function, traditionally seen as a support role, is now integral to the therapy itself, where factors such as timing, temperature control, and coordination are critical to treatment success. The shift necessitates a reevaluation of how supply chains are structured and managed, emphasizing the need for integrated solutions that can handle the complexities of advanced therapies.

Cryoport Systems is at the forefront of this evolution, expanding its role from a cryogenic shipping provider to a comprehensive supply chain platform that encompasses cryopreservation, biostorage, kit production, and logistics. IntegriCell®, a key service in this model, offers sponsors greater control earlier in the workflow, thereby mitigating risks associated with downstream processes. This integrated approach is essential as the industry grapples with the unique challenges posed by cell and gene therapies, where operational precision and reliability are paramount.